<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921387</url>
  </required_header>
  <id_info>
    <org_study_id>2728.00</org_study_id>
    <secondary_id>NCI-2013-01378</secondary_id>
    <secondary_id>2728.00</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01921387</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies</brief_title>
  <official_title>A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and the best dose of radiolabeled monoclonal
      antibody when given together with combination chemotherapy before stem cell transplant and to
      see how well it works in treating patients with high-risk lymphoid malignancies. Radiolabeled
      monoclonal antibodies, such as yttrium Y 90 anti-CD45 monoclonal antibody BC8, can find
      cancer cells and carry cancer-killing substances to them without harming normal cells. Giving
      chemotherapy before a stem transplant stops the growth of cancer cells by stopping them from
      dividing or killing them. Stem cells collected from the patient's blood are then returned to
      the patient to replace the blood-forming cells that were destroyed by the radiolabeled
      monoclonal antibody and chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the maximum-tolerated dose (MTD) of 90Y-BC8-DOTA (yttrium Y 90 anti-CD45
      monoclonal antibody BC8) (anti-cluster of differentiation [CD] 45) that can be delivered
      prior to myeloablative carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy
      and autologous stem cell transplant (ASCT) for patients with high-risk B-non-Hodgkin lymphoma
      (NHL), T-NHL, and Hodgkin lymphoma (HL).

      II. To evaluate the efficacy of 90Y-BC8-DOTA when administered at the estimated MTD prior to
      BEAM chemotherapy and ASCT for patients with high-risk B-NHL, T-NHL, and HL compared to
      historical controls treated with BEAM alone.

      SECONDARY OBJECTIVES:

      I. To describe the toxicity observed from the addition of 90Y-BC8-DOTA to BEAM.

      II. To optimize the protein dose (Ab) to deliver a favorable biodistribution in the majority
      of patients.

      III. To describe response rates and overall survival of patients with high-risk B-NHL, T-NHL,
      and HL following administration of 90Y-BC8-DOTA plus BEAM prior to ASCT.

      IV. To describe the impact of rituximab concentrations, B-cell depletion, and disease burden
      on CD45 targeting.

      V. To assess the correlation of lymphoma biomarkers with outcomes.

      VI. To evaluate the effects of nodal-targeted irradiation by 90Y-BC8-DOTA on immune
      reconstitution following ASCT.

      OUTLINE: This is a phase I, dose-escalation study of yttrium Y 90 anti-CD45 monoclonal
      antibody BC8 followed by a phase II study.

      Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 intravenously (IV) on day
      -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours
      twice daily (BID) on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and
      melphalan IV over 30 minutes on day -2. Patients then undergo autologous peripheral blood
      stem cell (PBSC) transplant on day 0.

      After completion of study treatment, patients are followed up at 3, 6, and 12 months and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2013</start_date>
  <completion_date type="Anticipated">July 26, 2021</completion_date>
  <primary_completion_date type="Actual">July 26, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose (MTD) of yttrium Y 90 anti-CD45 monoclonal antibody BC8, defined as the dose that is associated with a true dose-limiting toxicity (DLT) rate of 25%</measure>
    <time_frame>Within 30 days post-transplant</time_frame>
    <description>DLT is defined as a therapy-related grade III or IV Bearman (transplant) toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival following autologous stem cell transplant (ASCT)</measure>
    <time_frame>1 year</time_frame>
    <description>Will be compared to a historical control.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated dose to tumor sites based on the tumor to normal organ ratios derived from dosimetry estimates coupled with the absorbed dose to normal organs based on the administered activity of yttrium Y 90 anti-CD45 monoclonal antibody BC8</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be evaluated among all patients and among those treated at the estimated MTD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lowest antibody (yttrium Y 90 anti-CD45 monoclonal antibody BC8) dose (mg/kg) that is consistent with a favorable biodistribution rate &gt;= 80% in lymphoma patients</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>A favorable biodistribution in a given patient will be defined by the target tissue receiving higher radiation dose per unit-administered activity (cGy/mCi) relative to all critical normal organs (lung, liver, kidney, etc.).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Recurrent B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent T-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Refractory Hodgkin Lymphoma</condition>
  <condition>Refractory Mantle Cell Lymphoma</condition>
  <condition>Refractory T-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous PBSC transplant</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <other_name>autologous stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous PBSC transplant</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)</arm_group_label>
    <other_name>90Y Anti-CD45 MoAb BC8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a histologically confirmed diagnosis of B-NHL, T-NHL, or HL; only
             patients with classical HL must have documented histologic demonstration of CD45+
             cells adjacent to the Reed Sternberg cells; patients must have received at least one
             prior standard systemic therapy with documented recurrent or refractory disease;
             patients with mantle cell lymphoma (MCL), T-NHL, or other high-risk malignancies may
             be enrolled/transplanted in complete remission (CR)/first partial remission (PR1)

          -  Creatinine &lt; 2.0

          -  Bilirubin &lt; 1.5 mg/dL

          -  All patients eligible for therapeutic study must have a minimum of &gt;= 2 x10^6 CD34/kg
             autologous hematopoietic stem cells harvested and cryopreserved

          -  Patients must have an expected survival of &gt; 60 days and must be free of major
             infection

        Exclusion Criteria:

          -  Circulating human anti-mouse antibody (HAMA), to be determined before each infusion

          -  Systemic anti-lymphoma therapy given in the previous 30 days before the scheduled
             therapy dose with the exception of rituximab

          -  Inability to understand or give an informed consent

          -  Lymphoma involving the central nervous system

          -  Other serious medical conditions considered to represent contraindications to ASCT
             (e.g., abnormally decreased cardiac ejection fraction, diffusion capacity of carbon
             monoxide [DLCO] &lt; 50% predicted, etc.)

          -  Known human immunodeficiency virus (HIV) seropositivity

          -  Pregnancy or breast feeding

          -  Prior autologous or allogeneic bone marrow or stem cell transplant

          -  Prior radiation therapy (RT) &gt; 20 gray (Gy) to a critical organ within 1 year of
             enrollment

          -  Southwestern Oncology Group (SWOG) performance status &gt;= 2.0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay Gopal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2013</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

